1-2 of 2
Shogo Shigeta
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

Shogo Shigeta, Goldie Y.L. Lui, Reid Shaw, Russell Moser, Kay E. Gurley, Grace Durenberger, Rachele Rosati, Robert L. Diaz, Tan A. Ince, Elizabeth M. Swisher, Carla Grandori, Christopher J. Kemp
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (4): 691–703.
https://doi.org/10.1158/1535-7163.MCT-20-0809
Published: 01 April 2021
View article titled, Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Open the PDF for Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer

Xuewei Zhang, Kazuyuki Kitatani, Masafumi Toyoshima, Masumi Ishibashi, Toshinori Usui, Junko Minato, Mahy Egiz, Shogo Shigeta, Todd Fox, Tye Deering, Mark Kester, Nobuo Yaegashi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1): 50–59.
https://doi.org/10.1158/1535-7163.MCT-17-0173
Published: 01 January 2018
View article titled, Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer
Open the PDF for Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer in another window
Includes: Supplementary data